The effect of dual bronchodilatory therapy on the clinical control of chronic obstructive pulmonary disease in real clinical practice

Today, achieving clinical control in patients with chronic obstructive pulmonary disease (COPD) remains relevant. Thus, the results of a large multicenter study of clinical efficacy of dual bronchodilatory therapy in real practice conducted in Eastern Europe, including the Russian Federation, are of great interest.

Aim. Assessment of changes in the clinical control in patients with COPD receiving treatment with LABA/LAMA combination (tiotropium/olodaterol 5/5 μg via the Respimat® inhaler) in real clinical practice.

Methods. The study included patients (n = 1 476) with COPD older than 40 years who were prescribed tiotropium/olodaterol 5/5 μg via the Respimat® inhaler according to the current Russian and foreign clinical guidelines. The observation period was 6 weeks. The clinical control of COPD was assessed by the CCQ questionnaire, the patient’s general condition, the severity of dyspnea according to the mMRC scale, the incidence of using short-acting bronchodilators to relieve symptoms. The criterion for therapeutic success was a 0.4 point decrease in the CCQ score, the minimal clinically important difference

Results. The treatment with tiotropium/olodaterol 5/5 μg was successful, i.e., led to a decrease in the number of CCQ points by more than 0.4 points, in 89.84% of patients (95% CI 88.2 – 91.3 %; p < 0.0001). On average, the overall CCQ score between the first and second visit decreased by 1.31 ± 0.97 points, the severity of symptoms – by 1.39 ± 1.03 points, the functional state – by 1.2 ± 1.1 points, the mental condition – by 1.38 ± 1.31 CCQ points. Achievement of clinical control did not depend on comorbid pathology, disease severity, patient age, and the previous therapy.

Conclusion. The results obtained on a wide sample of patients from real practice confirmed the high clinical efficacy of tiotropium/olodaterol 5/5 μg in achieving clinical control of COPD.

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (2020 Report). Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf

2. Avdeev S.N., Aisanov Z.R., Belevskiy A.S. et al. [The concept of chronic obstructive pulmonary disease control as a decision-making tool and optimization of basic therapy in real clinical practice]. Terapevticheskiy arkhiv. 2020; 92 (1): 89–95. DOI: 10.26442/00403660.2020.01.000489 (in Russian).

3. Soler-Cataluña J.J., Alcázar-Navarrete B., Miravitlles M. The concept of control in COPD: a new proposal for optimising therapy. Eur. Respir. J. 2014; 44 (4): 1072–1075. DOI: 10.1183/09031936.00064414.

4. Avdeev S.N., Trushenko N.V. [New possibilities of dual bronchodilatory therapy in patients with chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv. 2019; 91 (3): 76–85. DOI: 10.26442/00403660.2019.03.000136 (in Russian).

5. Avdeev S.N., Trushenko N.V. [Effects of fixed combination of indacaterol/glycopyrronium in chronic obstruc tive pulmonary disease: state-of-the art review]. Pulmonologiya. 2018; 28 (2): 224–233. DOI: 10.18093/0869-0189-2018-28-2-224-233 (in Russian).

6. Avdeev S.N., Trushenko N.V. [Double bronchodilation – a new paradigm for long-term therapy of chronic obstructive pulmonary disease]. Prakticheskaya pul’monologiya. 2015; (3): 24–32. Available at: https://cyberleninka.ru/article/n/dvoynaya-bronhodilatatsiya-novaya-paradigma-dlitelnoy-terapii-hronicheskoy-obstruktivnoy-bolezni-legkih/viewer (in Russian).

7. van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/ LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21 (1): 101–108. DOI: 10.4104/pcrj.2011.00102.

8. Deas S.D., Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr. Opin. Pulm. Med. 2018; 24 (2): 130–137. DOI: 10.1097/MCP.0000000000000450.

9. Smid D.E., Franssen F.M., Houben-Wilke S. et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. J. Am. Med. Dir. Assoc. 2017; 18 (1): 53–58. DOI: 10.1016/j.jamda.2016.08.002.

10. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45 (4): 969–979. DOI: 10.1183/09031936.00136014.

11. Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109 (10): 1312–1319. DOI: 10.1016/j.rmed.2015.08.002.

12. Maltais F., Aumann J.L., Kirsten A.M. et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur. Respir. J. 2019; 53 (3): 1802049. DOI: 10.1183/13993003.02049-2018.

13. Troosters T., Bourbeau J., Maltais F. et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016; 6 (4): e010106. DOI: 10.1136/bmjopen-2015-010106.

14. Miravitlles M., Sliwinski P., Rhee C.K. et al. Predictive value of control of COPD for risk of exacerbations: An international, prospective study. Respirology. 2020; 25 (11): 1136–1143. DOI: 10.1111/resp.13811.

15. Soler X. Evaluation of changes in control status in COPD: An opportunity for early intervention. Chest. 2020; 157 (5): 1064–1066. DOI: 10.1016/j.chest.2020.03.017.

16. van der Molen T., Willemse B.W.M., Schokker S. et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes. 2003; 1: 13. DOI: 10.1186/1477-7525-1-13.

17. Kon S.S.C., Dilaver D., Mittal M. et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax. 2014; 69 (9): 793–798. DOI: 10.1136/thoraxjnl-2013-204119.

18. Trappenburg J.C.A., Touwen I., de Weert‐van Oene G.H. et al. Detecting exacerbations using the Clinical COPD Questionnaire. Health Qual. Life Outcomes. 2010; 8: 102. DOI: 10.1186/1477-7525-8-102. 19. Zhou Z., Zhou A., Zhao Y., Chen P. Evaluating the Clinical COPD Questionnaire: A systematic review. Respirology. 2017; 22 (2): 251–262. DOI: 10.1111/resp.12970.

19. Tsiligianni I.G., van der Molen T., Moraitaki D. et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm. Med. 2012; 12: 20. DOI: 10.1186/1471-2466-12-20.

20. Ringbaek T., Martinez G., Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD. 2012; 9 (1): 12–15. DOI: 10.3109/15412555.2011.630248.

21. Gaynitdinova V.V., Avdeev S.N., Neklyudova G.V. et al. [An impact of cardiovascular comorbidity on course and prognosis of chronic obstructive pulmonary disease]. Pul’monologiya. 2019; 29 (1): 35–42. DOI: 10.18093/0869-0189-2019-29-1-35-42 (in Russian).

22. Frith P.A., Ashmawi S., Krishnamurthy S. et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology. 2018; 23 (12): 1152–1159. DOI: 10.1111/resp.13374.

23. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI: 10.1056/NEJMoa1407154.

24. Tashkin D.P., Amin A.N., Kerwin E.M. Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15: 1225–1243. DOI: 10.2147/COPD.S244942.

25. Valipour A., Tamm M., Kociánová J. et al. Improvement in self-reported physical functioning with tiotropium/ olodaterol in Central and Eastern European COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; (14): 2343–2354. DOI: 10.2147/COPD.S204388.

26.

27.